ty -jour t1-在非ICU患者中对口服右塞米松进行辅助治疗，该患者患有社区获得的肺炎：一项随机临床试验JF-欧洲呼吸杂志JO -EUR RESSIR J DO -10.1183/13993003.02535-20202020 VL -58-2002535 AU- Wittermans，Esther Au -Vestjens，Stefan M.T.Au -Spoorenberg，Simone M.C.Au -Blok，Willem L. au -Grutters，Jan C. Au -Janssen，Rob Au -Rijkers，Ger T. au -Smeenk，Frank W.J.M.au -voorn，G。Paul au -van de garde，ewoudt M.W. au -bos，willem jan W. au-，y1-2021/08/01 ur -http：//www.qdcxjkg.com/content/58/2/2002535.Abstract N2-背景辅助性静脉皮质类固醇治疗已显示可降低住院的成年人的住院时间（LOS）（LOS）。我们的目的是评估口服地塞米松对LOS的影响以及这种作用是否取决于疾病的严重程度。在荷兰的四家教学医院中接受口服地塞米松（每天6毫克）或安慰剂4天。随机化（四个块）按CAP严重程度（肺炎严重程度指数I – III和IV – V）进行了分层。主要结果是LOS。在2012年12月至2018年11月之间，有401名患者被随机接受地塞米松（n = 203）或安慰剂（n = 198）。 Median LOS was shorter in the dexamethasone group (4.5 days, 95% CI 4.0–5.0 days) than in the placebo group (5.0 days, 95% CI 4.6–5.4 days; p=0.033). Within both CAP severity subgroups, differences in LOS between treatment groups were not statistically significant. The secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) versus 14 (7%); p=0.030); 30-day mortality did not differ between groups. In the dexamethasone group the rate of hospital readmission tended to be higher (20 (10%) versus 9 (5%); p=0.051) and hyperglycaemia (14 (7%) versus 1 (1%); p=0.001) was more prevalent.Conclusion Oral dexamethasone reduced LOS and ICU admission rate in adults hospitalised with CAP. It remains unclear for which patients the risk–benefit ratio is optimal.Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia (CAP) reduced length of stay and ICU admission rate. However, it remains unclear for which CAP subgroup the risk–benefit ratio is optimal. https://bit.ly/35tXfPX ER -